Home Medicine Growth Hormone Therapy and the Risk of Tumor Recurrence after Brain Tumor Treatment in Children
Article
Licensed
Unlicensed Requires Authentication

Growth Hormone Therapy and the Risk of Tumor Recurrence after Brain Tumor Treatment in Children

  • Tilman R. Rohrer , Thorsten Langer , Gerhard G. Grabenbauer , Michael Buchfelder , Matthias Glowatzki and Helmuth G. Dörr
Published/Copyright: December 22, 2010
Journal of Pediatric Endocrinology and Metabolism
From the journal Volume 23 Issue 9

ABSTRACT

To assess the effect of human growth hormone (hGH) therapy and other factors on tumor recurrence after treatment of pediatric brain tumors (BTs), we retrospectively analyzed data from 108 craniopharyngioma, medulloblastoma, and ependymoma patients. Risk factors were identified using multifactorial univariate regression analysis. Recurrences occurred in 41 and second malignant neoplasms in 4 patients. There were significant correlations for completeness of tumor removal and recurrence-free survival (RFS). 13/44 hGH-treated and 28/59 non-hGH-treated children relapsed. This difference was found only for medulloblastomas and accounted for by higher rates of incomplete tumor removal in non-hGH patients. Craniopharyngioma recurrence correlated only with RFS. Malignant BT recurrence correlated with completeness of tumor removal, chemotherapy, and RFS. 4 children developed SMNs, 3/4 after hGH therapy. Our regression model yielded accurate within-sample prediction of recurrence for 90% of the study population. We conclude that hGH therapy after treatment of pediatric BTs does not increase tumor recurrence risk.


Corresponding author: Professor Dr. Helmuth Dörr,

Published Online: 2010-12-22
Published in Print: 2010-September

© Freund Publishing House Ltd.

Articles in the same Issue

  1. The Soy That Surrounds Us: An Endless Debate
  2. Soy as an Endocrine Disruptor: Cause for Caution?
  3. Mass Ascites in Mulibrey Nanism
  4. Delayed Gastric Emptying in Patients with Prader Willi Syndrome
  5. Age and Sex Differences in Fat Distribution in Non-Obese Japanese Children
  6. Premature Thelarche in Taiwanese Girls
  7. Growth Hormone, Insulin Like Growth Factor-1, and Insulin-like Growth Factor-Binding Protein-3 Levels in the Neonatal Period: A Preliminary Study
  8. Bone Maturation in 1788 Children and Adolescents with Diabetes Mellitus Type 1
  9. Serum Thyroid Hormone Levels in Preterm Infants Born before 33 Weeks of Gestation and Association of Transient Hypothyroxinemia with Postnatal Characteristics
  10. Birth Length is a Predictor of Adiponectin Levels in Japanese Young Children
  11. Genotype-Phenotype Correlation in CAH Patients with Severe CYP21A2 Point Mutations in the Republic of Macedonia
  12. Benign Transient Hyperphosphatasemia of Infancy. A Common Benign Scenario, a Big Concern for a Pediatrician
  13. Scarcity Despite Wealth: Osteopetrorickets
  14. Growth Hormone Therapy and the Risk of Tumor Recurrence after Brain Tumor Treatment in Children
  15. Insulin Resistance and the Metabolic Syndrome in Obese Children Referred to an Obesity Center
  16. Severe Dietary Protein Sensitivity and Hyperinsulinemic Hypoglycemia in a Patient with Heterozygous Mutation in HADH Gene
  17. Neonatal Autoimmune Hypothyroidism: A Patient Report
  18. Adverse Effect of Phenytoin on Glucocorticoid Replacement in a Child with Adrenal Insufficiency
  19. Investigation of Acquired Von Willebrand Syndrome in Children with Hypothyroidism: Reversal after Treatment with Thyroxine
  20. Kabuki Syndrome and Crohn Disease in a Child with Familial Hypocalciuric Hypercalcemia
Downloaded on 11.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jpem.2010.150/html?lang=en
Scroll to top button